Edition:
United States

Profile: ARCA Biopharma Inc (ABIO.PH)

ABIO.PH on Philadelphia Stock Exchange

7.27USD
5 Jul 2019
Change (% chg)

-- (--)
Prev Close
$7.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,581
52-wk High
$16.64
52-wk Low
$0.30

ARCA biopharma, Inc. (ARCA), incorporated on March 16, 2004, is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors.

The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF. GENETIC-AF is a multi-center, randomized, double-blind, adaptive design clinical trial comparing the safety and efficacy of Gencaro against an active comparator, the beta-blocker Toprol XL (metoprolol succinate). Its GENETIC-AF clinical trial of Gencaro requires a companion diagnostic test to identify the patient's receptor genotype.

Company Address

ARCA Biopharma Inc

11080 Circle Point Rd Ste 140
WESTMINSTER   CO   80020-2769
P: +1720.9402200
F: +1720.2089261

Company Web Links